|
|
| The PinPointe(TM) FootLaser(TM) has received clearance from the U.S. Food and Drug Administration for the treatment of nail fungus (onychomycosis), which affects approximately 35 million Americans. Clinical studies show after a single PinPointe FootLaser treatment between 68% and 81% of patients experienced increased clear nail at six and 12 months, and 81 percent of all patients had sustained improvement at 12 months. For more information, visit www. PinPointeFootLaser.com. | |
| |
| Return to Release | Remove Frame | Source Image available | |